Merging with NextCure, Avere Therapeutics is based on a clinical-stage oral IL-23 receptor antagonist licensed from China's Hansoh Pharmaceutical for $120 million upfront.
Everything around China biotech really does seem to be speeding up.
On Tuesday, the former executive team behind Akero Therapeutics unveiled a new company, a …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
Why Did NextCure Stock 3X In One Session? - NextCure (NASDAQ:NXTC)
Fierce Pharma Asia—More AZ China deals; Kailera, Hengrui’s oral GLP-1 data; Scrutiny of Chinese trials
Akero team, backed by Fairmount, launches new immunology company
Insilico signs on with CDMO Bora in $2.5B AI drug discovery deal
